# EDGAR Filing Document

**Accession Number:** 0001326706
**File Stem:** 0001493152-26-004523
**Filing Date:** 2026-1
**Character Count:** 17766
**Document Hash:** a388580f31b2abd8c5d004a0aab32041
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-004523.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001493152-26-004523

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260130

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENvue Medical, Inc.
- **CENTRAL INDEX KEY:** 0001326706
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36445
- **FILM NUMBER:** 26583907

**BUSINESS ADDRESS:**
- **STREET 1:** 969 PRUITT AVE,
- **CITY:** TYLER
- **STATE:** TX
- **ZIP:** 77569
- **BUSINESS PHONE:** (914) 233-3004

**MAIL ADDRESS:**
- **STREET 1:** 969 PRUITT AVE,
- **CITY:** TYLER
- **STATE:** TX
- **ZIP:** 77569

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NanoVibronix, Inc.
- **DATE OF NAME CHANGE:** 20140425

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nano Vibronix, Inc.
- **DATE OF NAME CHANGE:** 20111206

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nano Vibronix Inc
- **DATE OF NAME CHANGE:** 20050510

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 30, 2026

**<u>ENvue Medical, Inc.</u>**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-36445</u> <u>01-0801232</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<u>969 Pruitt Ave Tyler, Texas</u> <u>77569</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (914) 233-3004

  <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share FEED | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

As previously disclosed in the Current Report on Form 8-K filed on July 22, 2025, in connection with the closing of the issuance and sale of the ENvue Medical,, Inc.'s (the "***Company***") Series H Convertible Preferred Stock, par value $0.001 per share (the "Preferred Stock") on July 18, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series H Convertible Preferred Stock with the Secretary of State of the State of Delaware (the "***Certificate of Designations***").

On January 30, 2026, the Company entered into that certain Amendment Agreement (the "***Amendment Agreement***") with the Required Holders (as defined in the Amendment Agreement). Pursuant to the Amendment Agreement, the Required Holders agreed to amend the Certificate of Designations by filing a Certificate of Amendment (the "***Certificate of Amendment***") to the Certificate of Designations with the Secretary of State of the State of Delaware to remove the Floor Price (as defined in the Certificate of Designations) in consideration of the holders of the Preferred Stock exercising $2,500,000 of the Additional Investment Right (as such concept is described in the Securities Purchase Agreement by and between the Company and the holders of the Preferred Stock on July 18, 2025, and which such form of Securities Purchase Agreement is filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 22, 2025).

On January 30, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, thereby amending the Certificate of Designations. The Certificate of Amendment became effective with the Secretary of State of the State of Delaware upon filing.

The foregoing descriptions of the Amendment Agreement and the Certificate of Amendment are qualified in their entirety by reference to the full text of each such document, copies of which are filed as Exhibit 10.1 and Exhibit 3.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

**Item 3.03 Material Modification to Rights of Security Holders.**

The matters described in Item 1.01 of this Current Report on Form 8-K related to the Preferred Stock and the Certificate of Amendment are incorporated herein by reference.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

The matters described in Item 1.01 of this Current Report on Form 8-K related to the filing of the Certificate of Amendment is incorporated herein by reference.

**Item 9.01** **Financial Statements and Exhibits.**

*(d) Exhibits.* 

---

| | |
|:---|:---|
| **Exhibit Number** | **Description of Exhibit** |
| 3.1 | [Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Preferred Stock.](ex3-1.htm) |
| 10.1 | [Form of Amendment Agreement, dated as of January 30, 2026, by and among the Company and the holders party thereto.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ENVUE MEDICAL, Inc** **.** | **ENVUE MEDICAL, Inc** **.** |
| Date: January 30, 2026 | By: | */s/ Doron Besser, M.D.* |
|  | Name: | Doron Besser, M.D. |
|  | Title: | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**Certificate of Amendment of**

**Certificate of Designations of**

**PREFERENCES, RIGHTS AND LIMITATIONS OF**

**Series H CONVERTIBLE Preferred Stock of**

**ENVUE MEDICAL, INC.**

Pursuant to Section 242 of the

Delaware General Corporation Law

This Certificate of Amendment to the Certificate of Designations of Preferences, Rights and Limitations of Series H Convertible Preferred Stock (the "***Amendment***") is dated as of January 30, 2026.

WHEREAS, the board of directors (the "***Board***") of ENvue Medical, Inc., a Delaware corporation (the "***Company***"), pursuant to the authority granted to it by the Company's Certificate of Incorporation (as amended, the "***Certificate of Incorporation***") and Section 151(g) of the Delaware General Corporation Law (the "***DGCL***"), has previously fixed the rights, preferences, restrictions and other matters relating to a series of the Company's preferred stock, consisting of 55,111 authorized shares of preferred stock, classified as Series H Convertible Preferred Stock (the "***Preferred Stock***") and the Certificate of Designations of Preferences, Rights and Limitations of the Preferred Stock (the "***Certificate of Designations***") was initially filed with the Secretary of State of the State of Delaware on July 18, 2025, evidencing such terms;

WHEREAS, pursuant to Section 8(j) of the Certificate of Designations, the Certificate of Designations or any provision thereof may be amended by obtaining the written consent of the majority of the holders of the Preferred Stock issued and outstanding on such date (the "***Required Holders***");

WHEREAS, the Required Holders pursuant to the Certificate of Designations have consented, in accordance with the DGCL, on January 30, 2026, to this Amendment on the terms set forth herein; and

WHEREAS, the Board has duly adopted resolutions proposing to adopt this Amendment and declaring this Amendment to be advisable and in the best interest of the Company and its stockholders.

NOW, THEREFORE, this Amendment has been duly adopted in accordance with Section 151 of the DGCL and has been executed by a duly authorized officer of the Company as of the date first set forth above to amend the terms of the Certificate of Designations as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. Section
 6(b) of the Certificate of Designations is hereby amended and restated to read as follows:

"(b) <u>Conversion Price</u>. The conversion price for the Preferred Stock shall equal $1.01, subject to adjustment herein (the "<u>Conversion Price</u>"); provided that, following the issuance of any Additional Shares, the Conversion Price shall be equal to 85% of the arithmetic average of the three (3) lowest VWAPs for the ten (10) Trading Days prior to the issuance of such Additional Shares (the "Adjusted Conversion Price")."

&nbsp;&nbsp;&nbsp;&nbsp;2. Section
 7(b) of the Certificate of Designations is hereby amended and restated to read as follows:

"(b) <u>Subsequent Equity Sales</u>. If, at any time while this Preferred Stock is outstanding, the Corporation or any Subsidiary, as applicable sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the "<u>Base Conversion Price</u>" and such issuances, collectively, a "<u>Dilutive Issuance</u>") (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Conversion Price shall be reduced to equal the Base Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance. If the Corporation enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase Agreement, the Corporation shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised. The Corporation shall notify the Holders in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 7(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the "<u>Dilutive Issuance Notice</u>"). For purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance, the Holders are entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether a Holder accurately refers to the Base Conversion Price in the Notice of Conversion."

[*Signature Page Follows*]

IN WITNESS WHEREOF, the Company has caused this Amendment to be signed by its duly authorized officer this 30<sup>th</sup> day of January, 2026.

---

| | |
|:---|:---|
| **ENVUE MEDICAL,** **INC.** | **ENVUE MEDICAL,** **INC.** |
| By: | */s/ Doron Besser, M.D.* |
| Name: | Doron Besser |
| Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**Amendment AGREEMENT**

This Amendment Agreement (this "<u>Agreement</u>"), dated as of January 30, 2026, is by and between ENvue Medical, Inc., a Delaware corporation (the "<u>Company</u>"), and the holder listed on the signature pages attached hereto (the "<u>Holder</u>").

WITNESSETH

Whereas, pursuant to that certain Securities Purchase Agreement, dated as of July 18, 2025 (the "<u>Purchase Agreement</u>"), the Holder was issued shares of Series H Convertible Preferred Stock, par value $0.001 per share (the "<u>Preferred Stock</u>"), the terms of which are set forth in the Certificate of Designations of the Preferred Stock (as amended, the "<u>Certificate of Designations</u>");

WHEREAS, in consideration for the Holder's exercise of an aggregate of [$2,500,000] of the Additional Investment Right (as such provision is described in Section 4.17 of the Purchase Agreement), the Company and the Holder desire to amend the Certificate of Designations to remove the Floor Price (as defined in the Certificate of Designations); and

WHEREAS, pursuant to Section 8(j) of the Certificate of Designations, the Certificate of Designations or any provision thereof may be amended by obtaining the written consent of the majority of the Holders of the Preferred Stock issued and outstanding on such date (the "<u>Required Holders</u>");

WHEREAS, the undersigned collectively hold at least a majority of the outstanding shares of Preferred Stock and thereby constitute the Required Holders.

Now, therefore, in consideration of the premises and mutual covenants and obligations hereinafter set forth, the parties hereto, intending legally to be bound, hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Definitions</u>.
 Capitalized terms used herein but not otherwise defined herein shall have the respective
 meanings given such terms in the Certificate of Designations.

&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Amendment to the Certificate of Designations</u>. The parties hereto hereby agree to amend the terms
 of the Preferred Stock as set forth in the Certificate of Designations of the Preferred Stock
 in the form attached hereto as <u>Exhibit A</u> (the " <u>Amendment</u> "). Upon
 the effectiveness of this Agreement, the Company shall promptly file the Amendment with the
 Secretary of State of the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Counterparts; Facsimile Execution</u>. This Agreement may be executed in one or more counterparts (including
 by electronic mail, in PDF or by DocuSign or similar electronic signature), all of which
 shall be considered one and the same agreement and shall become effective when one or more
 counterparts have been signed by each of the parties and delivered to the other parties.
 Counterparts may be delivered via facsimile, electronic mail (including any electronic signature
 covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
 Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission
 method and any counterpart so delivered shall be deemed to have been duly and validly delivered
 and be valid and effective for all purposes.

&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Governing Law</u>. THIS Agreement SHALL BE SUBJECT TO THE PROVISIONS
 REGARDING GOVERNING LAW SET FORTH IN SECTION 8(D) OF THE Certificate of Designations, AND
 SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, *MUTATIS MUTANDIS*.

&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Terms and Conditions</u>. Except as modified and amended herein, all of the terms and conditions
 of the Certificate of Designations shall remain in full force and effect.

[*Signature pages follow immediately*.]

[*Company Signature Page to Amendment Agreement*]

In witness whereof, the undersigned has executed and delivered this Agreement as of the date first above written.

---

| | |
|:---|:---|
| **Company**: | **Company**: |
| **ENVUE MEDICAL, Inc.** | **ENVUE MEDICAL, Inc.** |
| By: |  |
| Name: | Doron Besser, M.D. |
| Title: | Chief Executive Officer |

---

[*Investor Signature Page to Amendment Agreement*]

In witness whereof, the undersigned has executed and delivered this Agreement as of the date first above written.

---

| |
|:---|
| Name of Investor: |
| By: |
| Name of signatory: |
| Title: |

---

**Exhibit A**

**Form of Amendment to Certificate of Designations**